ARTICLE | Clinical News

NVC-422: Phase IIa data

July 26, 2010 7:00 AM UTC

In a double-blind, dose-ranging, Dominican Phase IIa trial in 129 patients ages 2-12 with impetigo due to Staphylococci infections, thrice-daily low-, mid- and high-dose topical NVC-422 for 7 days produced respective clinical response rates of 85%, 87% and 92% vs. a historical response rate of 30-50% for placebo. Bacterial response rates at the end of treatment were 87%, 89% and 95% for low-, mid- and high-dose NVC-422, respectively, and the response rate for the 10 patients with methicillin-resistant S. aureus (MRSA) infections who completed treatment was 100%. ...